tbuckley/cabot-search huggingface dataset:
Abstract 4013: The Impact of Atrial Fibrillation on the outcomes of patients suffering a second Myocardial Infarction
Authors: Yingzi Deng, William J Kostis, Alan C Wilson, Nora Cosgrove, Yu-Hsuan Shao, Abel Moreyra, John B Kostis
Journal: Circulation (2008)

In the past 20 years, significant increases in hospital admissions for atrial fibrillation (AF) and in survival of acute myocardial infarction (MI) have been observed. We examined the occurrence of AF and its effect on short and long term outcomes of first MI(FMI) and second MI(SMI). Hospitalized MIs from MIDAS (Myocardial Infarction Data Acquisition System, N=269,110) in New Jersey from 1986 to 2005 were included in the analysis. The rate of the co-exiting MI and AF and 30-day and 1 year mortality were investigated. Approximately 11 %( N=26,631) of FMI patients had a second event. The rate of co-existing AF for the FMI was 9.6% in 1986 and 16.2% in 2005, a 40.9% increase; while AF increased 60.4%, from 7.7% to 20.5% for SMI. Patients with AF were older (76.5 vs 69.3), more likely to be female (43.6% vs 39.4%), to have subendocardial infarction (58.5% vs 49.2%). Patients AF were less likely to be black in racial (4.2% vs 8.4%) and to receive percutaneous coronary interventions (PCI) (6.1% vs 10.4 %). There were more strokes (2% vs 0.9%) and heart failure hospitalizations (HF, 58% vs 39%) in the AF group(p&lt;0.0001). Thirty-day mortality rates (AF vs non-AF) were 20.9% and 13.8% for the FMIs; and 21.5% vs 14.2% for SMIs. One-year mortality rates were 37.4% and 20.5% at FMI, and 43.3% and 28.1% at the SMI, respectively. When adjusting for age, gender, race, MI site, PCI, year of MI, diabetes, stroke and HF, AF increased the 30 day mortality by 36%( OR1.36 95% CI 1.32–1.41) for FMI, and by 33% (OR 1.33(1.22–1.46)] for SMI. The effect of AF on mortality was more pronounced at 1 year [FMI 1.54(1.50 –1.58), SMI:1.44(1.34 –1.55)]. Current AF as well as the history of AF increased both 30-day [OR for current AF: 1.35(1.22–1.50), history of AF: 1.17(1.04 –1.32)] and 1-year mortality [current AF: 1.5(1.4 –1.6), history of AF: 1.21(1.11–1.33)]. The rate of AF in MI patients has increased, especially SMIs. AF remains as a strong predictor of worse outcome for patients suffering a second MI. Both the history of AF and current AF were associated with higher mortality in MI patients.
亚历山大技术课程、体育锻炼以及按摩（ATEAM）治疗慢性复发性腰背痛的随机对照试验
Authors: Paul, Little, George, Lewith, Fran, Webley, Maggie, Evans, Angela, Beattie, Karen, Middleton, Jane, Barnett, Kathleen, Ballard, Frances, Oxford, Peter, Smith
Journal: BMJ (2008)

目的确定亚历山大技术课程、按摩疗法以及按照医生运动处方在护士指导下进行体育锻炼对慢性或复发性腰背痛治疗的效果。设计析因随机试验。地点英格兰的64个全科医疗机构。参试者579例慢性复发性腰背痛患者；144例随机接受常规治疗，147例接受按摩治疗，144例接受6节亚历山大技术课程，144例接受24节亚历山大技术课程；每组均有半数患者随机给予运动处方。干预常规治疗（对照）、6次按摩、6或24节亚历山大技术课程以及按照医生运动处方在护士指导下进行体育锻炼。主要结局指标RolandMorris残疾评分（疼痛受损活动数）和疼痛天数。结果体育锻炼和亚历山大技术课程，而非按摩，1年时依然有效（与对照组RolandMorris残疾评分8.1比较：按摩组为-0.58，95％可信区间-1.94－0.77；6节亚历山大技术课程-1.40，-2.77－-0.03；24节亚历山大技术课程-3.4，-4.76－-2.03；体育锻炼组-1.29，-2.25－-0.34）。6节课程之后体育锻炼的疗效为单独24节亚历山大技术课的72％（Roland Morris残疾评分分别为-2.98和-4.14）。课程后前4周腰背痛天数减少（与对照组中位数21天相比，24节课程-18天，6节课程-10天，按摩组-7天）；而且生活质量显著改善。没有明显的损害报告。结论由注册教师提供的一对一亚历山大技术课程可使慢性腰背痛患者长期受益。6节亚历山大技术课程后辅以体育锻炼处方的效果接近24节亚历山大技术课程。
Molecular and Serological Examination of the Relationship of Human Herpesvirus 8 to Multiple Myeloma: orf 26 Sequences in Bone Marrow Stroma Are Not Restricted to Myeloma Patients and Other Regions of the Genome Are Not Detected
Authors: John F. Tisdale, A. Keith Stewart, Bruce Dickstein, Richard F. Little, Ian Dubé, D. Cappe, Cynthia E. Dunbar, Kevin E. Brown
Journal: Blood (1998)
Nutrition Recommendations and Interventions for Diabetes
Journal: Diabetes Care (2007)

Medical nutrition therapy (MNT) is important in preventing diabetes, managing existing diabetes, and preventing, or at least slowing, the rate of development of diabetes complications. It is, therefore, important at all levels of diabetes prevention. MNT is also an integral component of diabetes self-management education (or training). This position statement provides evidence-based recommendations and interventions for diabetes MNT. The previous position statement with accompanying technical review was published in 2002 and modified slightly in 2004. This statement updates previous position statements, focuses on key references published since the year 2000, and uses grading according to the level of evidence available...
Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer.
Authors: S. B. Zeliadt, N. K. Sekaran, C. G. Slatore, D. H. Au, D. Y. Wu, J. Crawford, G. H. Lyman, D. C. Dale
Journal: Journal of Clinical Oncology (2010)

6056 Background: The recently established VA Oncology Registry (VAOR) offers the ability to identify newly diagnosed patients with cancer treated at VA Medical Centers, for whom detailed clinical information can be linked to VA electronic medical data to evaluate treatment and outcomes of care. Methods: We compared male Veterans in the Pacific Northwest VAOR to male subjects in the Puget Sound Surveillance, Epidemiology, and End Results (SEER) Registry for the period 2000 through 2006. Women were excluded as they comprised 47% of SEER data but only 3% of VA patients with lung cancer. Results: We identified 1,715 Veterans and 7,864 men diagnosed with lung cancer in the Puget Sound SEER region between 2000 and 2006. Stage IV disease was common among Veterans and the SEER population (37% VAOR; 39% SEER) although stage information was missing for more subjects from SEER. Veterans were more likely to be diagnosed at an earlier age than the SEER population. Over 97% of Veterans were current or former smokers. The frequency of surgery was similar among stage I and II subjects from both data sources. Overall survival did not differ between VAOR and SEER. Within stage comparisons showed similar survival for stage III patients, and higher survival rates for individuals in SEER for all other stages. Conclusions: Demographic and survival data from the VAOR are comparable to the SEER Cancer Registry for men within the same geographic region. The VAOR incorporates detailed patient records on diagnosis, comorbidities, treatments, adverse events, and laboratory values from the VA Computerized Patient Record System (CPRS), making it a rich resource for assessing risk factors and determinants of clinical outcomes for patients with lung cancer and perhaps other types of cancer. Pacific Northwest VAOR N = 1,715 (%) Puget Sound SEER Registry N = 7,864 (%) Stage at diagnosis I 25 17 II 8 4 III 25 27 IV 37 39 Unknown 5 12 Histology Adenocarcinoma 21 28 Squamous 27 22 NSCLC (other than squamous or adenocarcinoma) 7 12 NSCLC–NOS 46 38 % White 88 89 % Smoking history 97 n/a Age <65 38 32 65-74 35 32 75+ 27 36 % Surgery stage I and II 75 77 5-yr survival (Age 55-74) Overall 16.0 16.2 Stage I 42.5 50.3 Stage II 31.4 38.8 Stage III 8.1 11.4 Stage IV 0.4 2.6 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech
Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.
Authors: S. Loi, B. Haibe-Kains, D. N. Brown, J. Metallo, L. X. Huan, C. Desmedt, L. Pusztai, M. Piccart, F. J. Esteva, C. Sotiriou
Journal: Journal of Clinical Oncology (2010)

522 Background: HER2 overexpression predicts response to anti-HER2 agents. Molecular profiling often suggests that ER+/HER2+ (double positive-DP) BC is a distinct entity from ER-/HER2+ BC. We investigated these differences and their potential clinical implications. Methods: HER2 overexpresion was defined by FISH ratio > 2.0 or mRNA. ER status was defined by ESR1 mRNA. We used 11 datasets of BC samples with gene expression (GE) and clinical outcome data (n = 1,110, 17% HER2+); 2 array CGH datasets (n = 309, 27%) and 74 HER2+ neoadjuvantly trastuzumab-treated patients. HER2+ BC cell lines treated with anti-HER2 agents were used to investigate in silico. Results: In systemically untreated BC patients, the DP had the worse outcome compared with the ER+/HER2- (p = 0.001); ER-/HER2- (p = 0.02) but also the ER-/HER2+ (p = 0.02) subgroups. There were significant molecular differences in HER2+BC according to ER status- DP vs. ER-/HER2+; 6.2% of whole genome GE and 1.1% copy number changes, FDR < 1%). In HER2+ BC, hypotheses.ESR1 gene expression was significantly inversely correlated with ERBB2 (R = -0.3; p = 0.02), EGFR (-0.6; p < 0.001) and gene sets of RAS (-0.4; p = 0.01), RAF (-0.8; p < 0.001), MAPK (-0.7; p < 0.001) and MEK (-0.4; p < 0.001) pathway activation. However, there were positive correlations between ESR1 and ERBB3 (0.7; p < 0.001) and AKT1 (0.4; p < 0.001). A gene set of PI3K/AKT pathway activation could predict pCR in trastuzumab-chemotherapy patients in DP (AUC = 0.8; p = 0.005) but not in the ER-/HER2+ (AUC = 0.6) group. HER2+ BC cell lines were treated with trastuzumab and lapatinib. BT474, ZR7530, SKBR3 (DP) showed decreased proliferation corresponding to decreased pAKT and pS6, but HCC1954 and HCC1569 (ER-) had less growth inhibition, pAKT and pS6 reduction. Furthermore, BT474 lines treated with fulvestrant to inhibit ER signaling were no longer sensitive to an AKT inhibitor (p = 0.001). Conclusions: In HER2+ BC patients, ER status defines distinct molecular and clinical phenotypes. ER signaling may antagonize EGFR/RAS/MAPK signaling, leading to increased PI3K/AKT output in the DP. Treatment may therefore be different for HER2+BC according to ER status. No significant financial relationships to disclose.
Serum Levels of Tumor Necrosis Factor and IL-1α and IL-1β in Diabetic Patients
Authors: Arshag D Mooradian, Richard L Reed, Keith E Meredith, Philip Scuderi
Journal: Diabetes Care (1991)

Objective To determine whether chronic hyperglycemia causes increased levels of serum tumor necrosis factor (TNF) and interleukin 1 α (IL-1 α) and IL-1 β. Research Design and Methods Sera were obtained from 59 diabetic patients, 44 chronically ill nondiabetic patients, and 34 age-matched healthy control subjects. Mononuclear cells were isolated from a subgroup of diabetic patients and healthy control subjects. Results Except for a modest increase in the prevalence of detectable serum TNF levels in diabetic patients, the serum cytokines measured in this study did not appear to be altered in diabetes. In vitro TNF production by mononuclear cells was not altered in diabetic patients. However, in vitro IL-1 β secretion, in response to lipopolysaccharides, was reduced. Conclusions Diabetes mellitus is not associated with significant changes in serum levels of TNF, IL-1 α, or IL-1 β. In vitro secretion of IL-1 β in response to lipopolysaccharides may be reduced in diabetes.
Diagnosis and natural course of allergy to cooked potatoes in children
Authors: L. F. A. De Swert, P. Cadot, J. L. Ceuppens
Journal: Allergy (2007)

Background: Allergy to heat stable potato proteins can cause severe allergic disease in children. Objective: To study diagnostic criteria for allergy to cooked potatoes and to describe its clinical characteristics and natural history. Methods: Thirty‐six children, aged 4–36 months, with atopic symptoms and having a positive potato‐CAP and/or skin prick test (SPT) were included. Potato allergy was documented by means of provocation, or elimination and reintroduction or an unequivocal clinical history. Potato‐CAP and SPT with a commercial extract were evaluated for diagnostic performance. Results: Presenting symptoms in children with proven potato allergy ( n = 17) were eczema (16 of 17), gastrointestinal complaints (eight of 17), urticaria and/or angioedema (five of 17), wheezing/rhinitis (three of 17) and anaphylaxis (two of 17). Fifteen children had previously diagnosed cow's milk protein allergy and were egg‐sensitized. Potato‐CAP at cut‐off &gt;2 kU/l provided a 100% sensitivity and a 62.5% specificity for diagnosis of potato allergy, while a SPT score ≥ 3 had a 100% sensitivity and a score ≥ 4 had a 100% specificity. Tolerance to cooked potato was achieved in 80% of subjects at age 16–102 months. Of 12 subjects having reached the age of 3 years during the study, 10 were re‐evaluated at age 3–6 years: seven of 10 subjects had developed clinical pollen allergy, compared with four of 18 atopic controls ( P &lt; 0.05). Conclusions: Potato‐CAP and SPT at specific cut‐off are valuable tools in the diagnosis of allergy to cooked potato. Most children with potato allergy develop tolerance at mean age of 4 years. Allergy to cooked potatoes is a risk factor for the development of pollen allergy.
Treating children with speech and language impairments
Authors: J. Law
Journal: BMJ (2000)

Papers p 923 

About 5-8% of children under the age of 5 have developmental impairments of speech and language. This proportion is higher than that for any other neurodevelopmental condition occurring at that age.1 Parents are concerned about these impairments, and the number of children being referred to speech and language therapy services is increasing.2

These impairments are characterised by a low level of speech and language skills. Such difficulties may occur secondary to disabilities such as cerebral palsy, sensorineural hearing loss, or autism. Impairment may also be the main symptom in a constellation of comorbid difficulties, such as challenging behaviour or otitis media.3

Although spontaneous remission of symptoms in primary speech and language disorders sometimes occurs many children will experience long term effects from these disorders. Studies of samples …
Abstract 13305: The Effect of Atrial Fibrillation Ablation on the Function of Left Atrium: Investigation Using Multi-Detector Computed Tomography
Authors: Masaharu Masuda, Koichi Inoue, Yasushi Koyama, Ryusuke Kimura, Yuko Toyoshima, Norihisa Ito, Atsunori Okamura, Katsuomi Iwakura, Kenshi Fujii
Journal: Circulation (2010)

Effect of atrial fibrillation (AF) ablation on left atrial (LA) function is still controversial. We measured LA volumes using multi-detector computed tomography (MDCT) which has excellent spatial and temporal resolution to estimate LA function. Methods: We enrolled consecutive 115 AF patients (92 paroxysmal and 23 persistent) undergoing AF ablation and performed with 64-slice MDCT in sinus rhythm at baseline and 3 months after the procedure. AF ablation included pulmonary vein isolation (PVI) in all patients and additional LA ablation in patients who had inducible and/or continuous AF or atrial tachycardia after PVI. To clarify the intensity of additional LA ablation, we counted the number of additional LA ablation lesions including LA roof line, mitral isthmus, and complex fractionated atrial electrocardiogram in each patient. Results: Maximum and minimum LA volumes decreased after AF ablation (Pre- vs. Post-ablation, 59.0 ± 20.4 to 53.3 ± 16.7 cm3, p = 0.001 and 33.5 ± 16.5 to 30.5 ± 13.6 cm3, p = 0.013...
Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial
Authors: Daniela Diverio, Vincenzo Rossi, Giuseppe Avvisati, Silvia DeSantis, Alessandra Pistilli, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Maria Concetta Petti, Alessandra Santoro, Pier Giuseppe Pelicci, Franco Mandelli, Andrea Biondi, Francesco Lo Coco
Journal: Blood (1998)
Dermatofibrosarcoma protuberans: 35 patients treated with Mohs micrographic surgery using paraffin sections
Authors: W.P. Tan, R.J. Barlow, A. Robson, H.A. Kurwa, J. McKenna, R. Mallipeddi
Journal: British Journal of Dermatology (2010)

Dermatofibrosarcoma protuberans (DFSP) has conventionally been treated with wide local excision. More recently Mohs micrographic surgery (MMS) has been advocated.To assess our departmental experience with DFSP in the context of a literature review relating to DFSP treated with MMS.This was a case review of 35 patients with DFSP treated between 1998 and 2009 with MMS using paraffin-embedded sections.Seventeen patients required one horizontal layer to clear their tumour, 10 patients needed two and eight patients needed three layers or more. The median preoperative clinical size was 6 cm(2) (range 0·75-54·8) and the median postoperative wound size was 46·8 cm(2) (range 4-145·2). Tumour persistence has not been observed in any of our patients after a median follow-up duration of 29·5 months (range 6-146).We present 35 DFSP patients, none of whom showed persistent tumour after treatment with 'slow' MMS using paraffin sections. We advocate MMS as the treatment of choice for DFSP, especially for tumours over the head and neck region where tissue conservation is particularly important.
Abstract 4600: Long-Term Clinical Outcomes Following Drug-eluting and Bare Metal Stenting in Patients With Chronic Kidney Disease in Massachusetts
Authors: David M Charytan, Manu R Varma, Treacy S Silbaugh, Ann F Lovett, Sharon-Lise T Normand, Laura Mauri
Journal: Circulation (2009)

Background: Patients with chronic kidney disease (CKD) have been underrepresented in randomized trials of drug-eluting stents (DES) relative to bare metal stents (BMS) and are at high risk for mort...
The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein
Authors: Keiko Kobayashi, David S. Sinasac, Mikio Iijima, Andrew P. Boright, Laila Begum, Jeffrey R. Lee, Tomotsugu Yasuda, Sayaka Ikeda, Ryuki Hirano, Hiroki Terazono, Michael A. Crackower, Ikuko Kondo, Lap-Chee Tsui, Stephen W. Scherer, Takeyori Saheki
Journal: Nature Genetics (1999)
A Longitudinal Study of Bullying of Sexual-Minority Youth
Authors: Mark A Schuster, Laura M Bogart, Marc N Elliott, David J Klein, Jeremy Y Feng, Susan R Tortolero, Sylvie Mrug, Terri H Lewis
Journal: New England Journal of Medicine (2015)

This longitudinal study involving surveys of fifth-, seventh-, and tenth-graders showed increased risks of bullying among gay, lesbian, or bisexual girls and boys.
The CDP-Ethanolamine Pathway Regulates Skeletal Muscle Diacylglycerol Content and Mitochondrial Biogenesis without Altering Insulin Sensitivity
Authors: Ahrathy Selathurai, Greg M. Kowalski, Micah L. Burch, Patricio Sepulveda, Steve Risis, Robert S. Lee-Young, Severine Lamon, Peter J. Meikle, Amanda J. Genders, Sean L. McGee, Matthew J. Watt, Aaron P. Russell, Matthew Frank, Suzanne Jackowski, Mark A. Febbraio, Clinton R. Bruce
Journal: Cell Metabolism (2015)
Abstract 3664: Mitochondrial p27 Is Required For Endothelial Energy Metabolism And Cell Migration
Authors: Ioakim Spyridopoulos, Joachim Altschmied, Vicente Andres, Judith Haendeler
Journal: Circulation (2008)

The migratory capacity of endothelial cells (EC) is a key prerequisite for the growth of new blood vessels during neovascularisation of ischemic and/or tumor tissues. Recently, mitochondria have been identified as signalling organelles in EC, which may contribute to migratory capacity. Therefore, the aim of this study was to investigate whether a molecular link exists between mitochondrial energy metabolism and migratory capacity of EC. To determine whether mitochondria are required for migratory capacity, we incubated EC with 50 ng/ml ethidiume bromide (EtBr) in the presence of uridine to deplete mitochondrial DNA (mtDNA) and, thereby, destroy active mitochondria. EC, which were depleted of mtDNA, did not migrate in a scratch wound assay (− EtBr: 22 +/− 3 migrated cells; + EtBr: 0.15 +/− 0.1 migrated cells). Since protein translocation is a major mechanism for modulating the functional capacity of the mitochondria, we hypothesized that induction of migration by the promigratory stimulus vascular endothelial growth factor (VEGF) leads to translocation of proteins to mitochondria. Recent studies demonstrated that a non-nuclear pool of p27 exerts biological activities including increase of migratory capacity independent of its cell cycle inhibitory activity. Stimulation of EC with VEGF induced a 2.5 +/− 0.4-fold increase in mitochondrially localized p27 protein. Reducing p27 expression by two different siRNAs completely abrogated VEGF-induced migration of EC (98 +/− 2 % inhibition). Next, we cloned p27 into a mitochondrial targeted vector (p27mito) to exclusively overexpress p27 in the mitochondria. Overexpression of p27mito stimulated mitochondrial ATP biosynthesis (3.24 +/− 1.06-fold empty vector), increased mitochondrial membrane potential and enhanced migratory capacity of EC to a similar extent as compared to VEGF. Cells overexpressing p27mito did not demonstrate further increased migratory capacity in response to VEGF. Finally, only p27mito but not nuclear-targeted p27 overexpression rescued the impaired migratory capacity after siRNA-mediated genetic ablation of endogenous p27 expression. These data demonstrate a novel role of mitochondrial p27 as a molecular link between cellular energy metabolism and migratory capacity of EC.
Immunoassay of circulating terminal transferase in patients with acute lymphoblastic leukemia: A new technique for diagnosis
Authors: Sanford A. Stass, Stephen C. Peiper, F.J. Bollum
Journal: American Journal of Hematology (1980)

Abstract The measurement of circulating terminal deoxynucleotidyl transferase (TdT) antigen can be accomplished by the use of an ELISA immunoassay system. TdT was present in either peripheral or bone marrow plasma of five patients with acute lymphoblastic leukemia (ALL) and absent from normal controls using ELISA. The assay was sensitive to a level of 20 ng/ml. The ALL patient values ranged from 160 ng/ml to 420 ng/ml. Use of ELISA for quantitation of TdT may have important diagnostic implications in patients with ALL.
Relationship of Fitness and Body Mass Index to Cardiac Disease
Authors: Earl H Schwark
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal